A three-year-old boy from California, Oliver Chu, has amazed medical experts after becoming the first person globally with Hunter syndrome to receive a pioneering gene therapy designed to halt the disease’s progression. The rare, inherited disorder, also known as MPS II, gradually damages the body and brain, often leading to death before the age of 20 in severe cases.

Oliver’s treatment represents a breakthrough: scientists in Manchester modified his own cells to produce an enzyme his body could not previously make. A year after the procedure, he is showing near-normal development, including cognitive and motor improvements, offering hope to families affected by this devastating condition.

Hunter Syndrome: Rare and Devastating

Hunter syndrome is caused by a genetic mutation that prevents the production of iduronate-2-sulfatase (IDS), an enzyme critical for breaking down large sugar molecules in cells. Without IDS, these molecules accumulate, causing damage to organs, bones, joints, and the nervous system. Symptoms typically appear around age two, including stiff limbs, short stature, delayed speech, and progressive cognitive decline. The condition almost exclusively affects boys, with an incidence of approximately one in 100,000 male births.

Until now, treatment options were limited. Enzyme replacement therapy, such as Elaprase, can slow some physical effects but does not cross the blood-brain barrier and cannot prevent cognitive decline. Treatments cost around £300,000 per patient annually.

The Gene Therapy Process

Oliver’s therapy began in December 2024 at the Royal Manchester Children’s Hospital. Doctors removed a portion of his stem cells using a machine designed for precise collection. These cells were then sent to Great Ormond Street Hospital in London for genetic modification.

In the lab, scientists inserted a functional copy of the IDS gene into a harmless virus, which served as a delivery mechanism. The virus then transferred the gene into Oliver’s stem cells. Importantly, the gene was modified to allow the enzyme to cross the blood-brain barrier, addressing both physical and neurological symptoms.

By February 2025, the gene-modified stem cells were returned to Manchester for infusion. Oliver received two infusions via a catheter in his chest, each containing approximately 125 million modified stem cells. The procedure was completed in minutes, and Oliver remained calm, watching cartoons during the treatment.

Early Signs of Improvement

By May 2025, follow-up testing indicated significant progress. Oliver displayed improved mobility, speech, and social engagement. Crucially, he no longer required weekly enzyme infusions, as his body had begun producing the missing IDS enzyme naturally.

His mother, Jingru, described the changes as “amazing,” while his father, Ricky, emphasized the rapid improvement in cognitive and physical abilities. Oliver’s older brother, Skyler, also diagnosed with Hunter syndrome, continues to receive conventional infusions but is not yet eligible for gene therapy targeting the brain.

Ongoing Monitoring and Future Plans

Oliver will continue regular check-ups every three months to monitor his enzyme production and neurological development. The clinical trial includes five boys from the US, Europe, and Australia, all of whom will be observed for at least two years. If successful, researchers plan to partner with biotech companies to make the therapy widely available.

Professor Simon Jones, co-leader of the trial, stressed cautious optimism: “Things are as good as they could be at this point, but we need to monitor carefully. We are encouraged by his progress in learning, mobility, and overall health.”

A Trial That Nearly Never Happened

The gene therapy originated from more than 15 years of research led by Professor Brian Bigger at the University of Manchester. Initially, a partnership with US biotech Avrobio faced setbacks due to poor results in a separate gene therapy trial and funding shortages, putting the first-in-human trial in jeopardy.

British charity LifeArc intervened with £2.5 million in funding, allowing the trial to proceed. Dr Sam Barrell, CEO of LifeArc, highlighted the challenges faced by patients with rare diseases, noting that 95% of such conditions have no effective treatments.

Hope for Families Affected by Hunter Syndrome

For the Chu family, the successful gene therapy has transformed daily life. Oliver now produces the missing enzyme, enjoys improved mobility, and engages fully with his surroundings. His parents hope Skyler may one day benefit from a similar treatment.

Ricky Chu reflected on the journey: “I would walk to the end of the earth, backwards, forwards, upside down, barefoot, to make sure my kids have a better future.”

The trial represents a landmark achievement in gene therapy, with potential applications for other rare genetic disorders, including MPS I (Hurler syndrome) and MPS III (Sanfilippo syndrome). Oliver’s story underscores the promise of genetic medicine in changing the outlook for children with previously untreatable conditions.

Source: BBC – Boy with rare condition amazes doctors after world-first gene therapy

The post Three-Year-Old Thrives After World-First Gene Therapy for Rare Hunter Syndrome appeared first on Journos News - Breaking News, World News, Top Stories, Todays Headlines and Flash Reports.

The study, conducted by scientists at the University of Texas MD Anderson Cancer Center and the University of Florida, found that patients with advanced lung or skin cancer lived significantly longer if they received an mRNA-based COVID-19 vaccine within 100 days of starting immune checkpoint inhibitor therapy.

Researchers say the finding, though preliminary, points to a potential secondary benefit of mRNA vaccine technology: improving the body’s ability to fight tumors.

How mRNA Vaccines May Strengthen Cancer Treatment

The study’s lead author, Dr. Adam Grippin of MD Anderson, explained that the vaccines appeared to “activate immune cells throughout the body,” effectively priming them to recognize and attack cancer cells.

“The vaccine acts like a siren to activate immune cells,” Grippin said. “We’re sensitizing immune-resistant tumors to immune therapy.”

Unlike traditional vaccines that use weakened or inactivated viruses, mRNA vaccines deliver genetic instructions prompting the body’s cells to produce a harmless version of a viral protein. This process triggers a strong immune response — a mechanism scientists believe could also improve how the body targets tumor cells when combined with immunotherapy drugs.

A Promising Link Between mRNA Shots and Checkpoint Inhibitors

The team reviewed medical records from nearly 1,000 patients undergoing treatment for advanced cancers at MD Anderson. Those who had received a Pfizer or Moderna COVID-19 shot showed notably better outcomes compared to those who had not been vaccinated.

For lung cancer patients, vaccinated individuals were nearly twice as likely to survive three years after beginning treatment compared to their unvaccinated counterparts. Among melanoma patients, vaccinated individuals also showed longer survival times, though the exact median remains unclear because many were still alive when data analysis ended.

Notably, patients who received non-mRNA vaccines, such as influenza shots, did not experience similar benefits — suggesting that the mRNA component itself may play a unique role in enhancing immune response.

Scientific Reactions and Future Directions

Experts not involved in the study said the results add to growing evidence that mRNA technology could have broad applications beyond infectious diseases.

“This research offers a very good clue that maybe an off-the-shelf approach could work,” said Dr. Jeff Coller, an mRNA specialist at Johns Hopkins University. “What it shows is that mRNA medicines are continuing to surprise us in how beneficial they can be to human health.”

The MD Anderson and University of Florida team is now preparing a more extensive clinical trial to determine whether pairing mRNA vaccines with checkpoint inhibitors should become a standard treatment approach.

Checkpoint inhibitors work by disabling the “invisibility cloak” that allows some cancer cells to evade immune detection. However, not all patients respond to these drugs. Researchers hope mRNA vaccines could help stimulate immune systems in those whose cancers are resistant.

A Step Toward Future Cancer mRNA Vaccines

Scientists have long been developing personalized mRNA cancer vaccines, designed to teach the immune system to recognize the specific mutations unique to an individual’s tumor. The new findings suggest that even non-personalized mRNA vaccines, such as COVID-19 shots, may help generate broader immune activation beneficial to some cancer patients.

Grippin said his team first noticed this effect while developing tumor-targeting mRNA therapies in Florida. They observed that even vaccines without a custom-designed cancer target still appeared to boost immune activity against tumors — prompting them to investigate whether coronavirus vaccines might produce a similar outcome.

While researchers caution that the results do not apply to all cancers or all patients, the study could pave the way for new dual-use mRNA therapies that protect against infectious diseases while improving cancer outcomes.

Policy Context and Ongoing Debate

The findings come amid continued public debate over the role of mRNA vaccine technology. U.S. Health Secretary Robert F. Kennedy Jr. has expressed skepticism about the technology and recently announced a $500 million reduction in federal funding for some of its applications.

Nevertheless, researchers say the data from the Nature study reinforces the growing medical consensus that mRNA platforms may represent one of the most versatile tools in modern medicine.

As more research emerges, scientists hope to determine which cancer types and treatment combinations might benefit most from mRNA-based interventions — potentially transforming how the immune system is harnessed to fight both viruses and tumors.

Source: AP News – COVID-19 vaccines may help some cancer patients fight tumors

The post COVID-19 Vaccines May Boost Cancer Treatment Effectiveness, Study Finds appeared first on Journos News - Breaking News, World News, Top Stories, Todays Headlines and Flash Reports.

In a major step forward for women’s health, the U.S. Food and Drug Administration has approved the Teal Wand — the first at-home device for cervical cancer screening. This breakthrough means women may soon be able to skip the speculum and stirrups and screen for cervical cancer from the comfort of their own home.

A Game-Changer for Cervical Cancer Screening

Developed by Teal Health, the Teal Wand allows users to collect their own vaginal samples at home and send them to a lab for HPV testing. The device will be included in Teal Health’s upcoming at-home screening kit, which will be available by prescription starting this June — launching first in California, with plans to expand across the U.S.

“This is the same test, with the same accuracy as in-clinic collection — but now you can do it from home,” said Teal Health CEO Kara Egan. “It gives women more options, especially through telehealth, and increases access to essential care.”

How It Works

Here’s how the process unfolds:

1. Request a Kit: Patients begin by visiting Teal Health’s website to request a kit.
2. Telehealth Visit: A quick consultation with a provider results in a prescription.
3. At-Home Collection: The patient uses the Teal Wand to collect a sample in private.
4. Mail to Lab: The sample is sent to a lab and analyzed using Roche’s HPV testing platform.
5. Results & Follow-Up: Results are reviewed by a clinician and shared with the patient. If needed, follow-up care is arranged.

Why It Matters

HPV (human papillomavirus) is the leading cause of cervical cancer, and early detection is critical. Yet millions of people in the U.S. are not up to date on their screenings. According to the CDC, about one in four adults fall behind on cervical cancer screening guidelines.

“This new test could be a game-changer,” said Dr. Ami Vaidya, co-chief of gynecologic oncology at Hackensack University Medical Center. “Some women avoid Pap smears due to discomfort or fear. Giving them a reliable at-home option could increase regular screenings, especially for those without easy access to a doctor.”

Support from Experts

The American Cancer Society praised the FDA’s decision.
“Most cervical cancers are found in people who were never screened or haven’t been screened recently,” said Dr. William Dahut, the organization’s chief scientific officer. “This at-home test adds a powerful tool in our fight against a potentially deadly disease.”

Understanding Cervical Cancer Screening

Cervical cancer screening typically involves:

• Pap tests (cytology): Detects abnormal cell changes in the cervix.
• HPV testing: Checks for the virus that can cause those changes.

The U.S. Preventive Services Task Force recommends:

• Women ages 21–29: Pap test every 3 years.
• Women ages 30–65: Either Pap test every 3 years, HPV test every 5 years, or both tests every 5 years.

Teal Health’s self-collection kit is designed to match the accuracy of these traditional methods while removing barriers like scheduling appointments or facing uncomfortable procedures.

What’s Next?

Teal Health is currently in talks with insurance providers to cover the cost of the kit. For those without insurance, pricing will be announced soon. A waitlist is already open on the company’s website.

With FDA approval now in place, the future of cervical cancer screening is looking more accessible — and more comfortable — than ever.

Source: CNN – FDA approves first cervical cancer screening device that can be used at home, company says

The post FDA Approves First At-Home Test for Cervical Cancer Screening appeared first on Journos News - Breaking News, World News, Top Stories, Todays Headlines and Flash Reports.

Is your doctor using artificial intelligence (AI) to help diagnose you? Could AI be summarizing your medical visits? While the use of AI in healthcare is still relatively new, its applications are expanding rapidly. However, many patients remain skeptical. A 2023 survey revealed that most Americans feel “significant discomfort” about AI-assisted healthcare.

Despite these concerns, AI is not going away. As technology continues to evolve, it is important to understand how AI is already being used in medical care, the potential benefits, and the associated risks.

To explore this, we spoke with Dr. Leana Wen, a CNN wellness expert, emergency physician, and adjunct associate professor at George Washington University. She provided valuable insights into AI’s role in diagnosis, treatment, and healthcare administration.

Dr. Wen explains that AI in healthcare generally falls into two categories: predictive AI and generative AI.

Predictive AI uses mathematical models and pattern recognition to anticipate patient outcomes. For example:

• Pneumonia Diagnosis: AI can analyze a patient’s medical history and clinical data to predict whether hospitalization is necessary.
• Sepsis Detection: Hospitals have implemented AI tools that detect sepsis early, reducing the time needed to administer life-saving treatments.
• Deterioration Monitoring: AI systems, like those used by Kaiser Permanente, track vital signs and lab results to alert medical teams when a patient’s condition is worsening.

Generative AI, like ChatGPT, creates human-like responses and summaries. In healthcare, it can:

• Summarize patient information and medical histories.
• Generate easy-to-understand instructions for patients.
• Assist doctors with drafting medical documentation and prior authorization letters for insurance approvals.

Although AI has impressive capabilities, concerns remain about “hallucinations,” where AI generates misleading or incorrect information. This underscores the need for careful validation before AI-based decisions are applied to patient care.

AI is already making a significant impact in diagnostics and treatment. Here are a few notable examples:

1. Colon Cancer Screening

• AI is improving colonoscopy accuracy by identifying and flagging potentially cancerous polyps in real-time. Studies have shown that AI-assisted colonoscopies reduce the rate of missed polyps, increasing early cancer detection.

2. Breast Cancer Detection

• AI is assisting radiologists in reading mammograms. Some AI-supported screening tools have been found to be as accurate as two trained radiologists and may improve cancer detection while reducing clinician workload.

3. AI for Sepsis and Patient Monitoring

• Hospitals are deploying AI-driven early warning systems to detect sepsis—an often-fatal infection—at an earlier stage, improving survival rates.
• Predictive AI is helping hospitals monitor critically ill patients, alerting medical teams when a patient’s condition deteriorates.

AI is also transforming healthcare beyond diagnostics.

• Ambient AI technology listens to doctor-patient conversations and drafts medical notes, saving time and improving efficiency.
• AI helps draft insurance authorization letters, reducing administrative burdens and allowing doctors to focus more on patient care.

While AI streamlines processes, concerns exist about its use in insurance claims. AI might assist insurance companies in processing claims, but it could also be used to deny coverage, making it harder for patients to appeal decisions. This highlights the need for strict regulations and oversight.

Patients may already be interacting with AI in their medical visits, whether through predictive algorithms influencing treatment decisions or AI-powered chatbots managing appointment scheduling. Here’s what you can do:

• Ask your doctor about how AI is being used in your healthcare.
• Review consent forms for AI-related disclosures.
• Know your privacy rights—medical records are protected under HIPAA laws in the U.S.

AI has the potential to revolutionize healthcare, but it must be used responsibly. While AI-driven innovations are improving diagnostics, treatment, and hospital efficiency, ongoing scrutiny is essential to ensure that AI tools are safe, accurate, and ethical.

Regulators, healthcare professionals, and technologists must work together to balance AI’s benefits with necessary precautions. As AI continues to evolve, the key question remains: How can we harness its power while maintaining patient trust and safety?

Source: CNN – Doctor explains how artificial intelligence is already being deployed in medical care

The post How AI is Changing Healthcare: What Patients Need to Know appeared first on Journos News - Breaking News, World News, Top Stories, Todays Headlines and Flash Reports.

A Breakthrough in Pain Relief

The U.S. Food and Drug Administration (FDA) has approved suzetrigine, the first new type of pain reliever in over two decades. This non-opioid medication, developed by Vertex Pharmaceuticals, provides an alternative for managing acute pain without the risk of addiction.

Marketed under the brand name Journavx, suzetrigine is a 50-milligram prescription pill taken every 12 hours after an initial larger dose.

Why This Approval Matters

Dr. Jacqueline Corrigan-Curay, acting director of the FDA’s Center for Drug Evaluation and Research, emphasized the importance of this approval:

“A new non-opioid analgesic for acute pain offers an opportunity to mitigate certain risks associated with using opioids and provides patients with another treatment option.”

This move aligns with the FDA’s efforts to combat the opioid crisis by promoting safer pain management alternatives.

How Suzetrigine Works

Unlike opioids, which dull pain by acting on the brain, suzetrigine targets pain at its source by blocking pain-signaling nerves before they can transmit pain messages to the brain.

Dr. Sergio Bergese, an anesthesiologist at Stony Brook University, explained:

“This drug interrupts the pain pathway so that even though the tissue injury exists, the brain doesn’t recognize it as pain.”

Crucially, suzetrigine does not produce euphoria or a “high,” reducing the risk of dependence and addiction.

Inspired by a Rare Genetic Mutation

The breakthrough behind suzetrigine stemmed from a Pakistani family with a rare genetic condition. Members of this family could walk on hot coals without experiencing pain due to a mutation in their sodium channels—the same channels responsible for transmitting pain signals.

This discovery led researchers to develop suzetrigine, which works by blocking a specific sodium channel that only carries pain signals, leaving other sensations like heat and touch unaffected.

Dr. Stephen Waxman of Yale University described it as a major advancement:

“This provides proof of concept that a sodium-channel blocker can reduce pain in humans, opening the door for even more effective medications in the future.”

How Effective Is Suzetrigine?

Suzetrigine has been tested in multiple clinical trials, including:

1. Post-Surgical Pain Relief
   • In two studies with 600 participants, suzetrigine reduced pain as effectively as Vicodin (a combination of acetaminophen and the opioid hydrocodone).
   • Participants reported about a 50% reduction in pain levels.
2. Chronic Pain & Sciatica
   • A smaller study on sciatica patients showed mixed results, with pain reduction similar to a placebo.
   • Vertex Pharmaceuticals insists ongoing research suggests the drug may work for other types of chronic pain, including diabetic neuropathy.

Dr. Kimberley Mauer, an anesthesiologist at Oregon Health & Science University, highlighted the significance:

“The more options we have, the better we’re able to treat each and every patient.”

Availability & Cost

• Pricing: $15.50 per 50-mg pill
• Insurance Coverage: Still uncertain; patient assistance programs will be available

Dr. Mauer cautioned that insurance coverage could impact access:

“It might limit some patients from getting it. We’ll have to wait and see how it plays out in the market.”

The Future of Pain Management

Suzetrigine represents a significant step toward safer pain relief options, particularly as the medical community seeks alternatives to opioids.

With this approval, researchers hope to develop even better non-opioid painkillers, offering relief without the risks of addiction.

Source

The post New Non-Opioid Pain Medication Gets FDA Approval appeared first on Journos News - Breaking News, World News, Top Stories, Todays Headlines and Flash Reports.

Scientists have made a groundbreaking discovery about Huntington’s disease, a fatal hereditary brain disorder. This research sheds new light on why the disease, caused by a known genetic mutation, remains dormant for decades before wreaking havoc on nerve cells in the brain.

The Mystery of Delayed Onset

Huntington’s disease is linked to a mutation in a specific gene. Despite being present from birth, the disorder typically doesn’t manifest until ages 30 to 50, leaving researchers puzzled.

A recent study reveals that the mutation is initially harmless but gradually worsens over time. As the mutation grows, it eventually reaches a critical threshold, producing toxic proteins that kill brain cells.

Dr. Mark Mehler, director of the Institute for Brain Disorders and Neural Regeneration at Albert Einstein College of Medicine, called the research a “landmark study,” stating it resolves long-standing questions in the field.

Symptoms and Progression

Huntington’s disease affects movement, cognition, and behavior, leading to symptoms such as:

• Involuntary movements
• Unsteady gait
• Personality changes
• Impaired judgment

The condition worsens over 10 to 25 years, eventually becoming fatal.

The Study: Key Findings

The research, conducted by scientists at the Broad Institute of MIT and Harvard, McLean Hospital, and Harvard Medical School, analyzed brain tissue from 53 individuals with Huntington’s and 50 without it. The team focused on the gene mutation, which involves a repeated three-letter DNA sequence, CAG.

Key findings include:

1. Normal vs. Mutated DNA: In healthy individuals, the CAG sequence repeats 15–35 times. In Huntington’s patients, it repeats 40 or more times.
2. DNA Expansion Over Time: Mutated DNA expands slowly during childhood but accelerates as it grows past 80 repeats. At around 150 repeats, it becomes toxic, causing neurons to die.
3. Critical Threshold: The severity and onset age of Huntington’s are linked to the number of repeats. The longer the sequence, the earlier symptoms appear.

“These findings were really surprising, even to us,” said Steve McCarroll, co-senior author of the study published in Cell.

Challenges in the Field

Researchers noted initial skepticism from peers since previous studies suggested that expansions of 30–100 CAG repeats were necessary—but not sufficient—to cause Huntington’s. This study confirms that only expansions exceeding 150 CAGs lead to the disease.

Implications for Treatment

Huntington’s disease currently has no cure, and treatments focus on managing symptoms. Experimental drugs targeting the protein produced by the mutated gene have underperformed in trials, possibly because only a small number of cells produce the toxic protein at a time.

Researchers now believe targeting DNA repeat expansion may offer a better approach. Slowing or stopping these expansions could delay or prevent the disease.

“Many companies are starting or expanding programs to try to do this,” said McCarroll.

Hope for the Future

The discovery provides a roadmap for new therapies aimed at addressing the root cause of Huntington’s. While challenges remain, the findings mark a significant step forward in understanding and potentially treating this devastating disease, which affects an estimated 41,000 Americans.

Source

The post Breakthrough Discovery Reveals Cause of Huntington’s Disease appeared first on Journos News - Breaking News, World News, Top Stories, Todays Headlines and Flash Reports.

Chinese scientists have made significant progress in fertility research by using stem cell transplantation to extend the reproductive lifespan in female monkeys. This breakthrough could provide new options for women struggling to conceive, especially as the average age for having children continues to rise.

The study, conducted by researchers from the Chinese Academy of Sciences and published in Cell Discovery, addresses the issue of ovarian aging, which naturally affects female fertility. As the ovaries age, they produce fewer eggs and hormones, leading to menopause and related health issues. Currently, there is no effective treatment to fully restore ovarian function.

Stem cells have shown promise in treating premature ovarian aging, so researchers investigated whether these treatments could benefit naturally aging ovaries. In the study, they transplanted M-cells—stem cells derived from human embryonic cells with strong immune and anti-inflammatory properties—into the ovaries of aging crab-eating macaques, a type of monkey with a reproductive aging pattern similar to humans.

The results were promising. The treated monkeys showed improved hormone levels, more active ovarian follicles, reduced ovarian fibrosis, and even healthier overall reproductive functions. One monkey even conceived and gave birth, highlighting the treatment’s potential.

With the average age of first-time mothers rising—27 in the United States, nearly 29 in Australia, and over 32 in South Korea—more women are experiencing fertility challenges as ovarian function begins to decline around their late 30s to mid-40s. In China, where the average age for first-time mothers is now over 27, regions like Shanghai see averages above 30.

Current treatments, like hormone replacement therapy, can help ease menopausal symptoms but carry risks such as heart disease, stroke, and breast cancer. Researchers aim to find safer, more effective treatments, especially given that ovarian aging can lead to serious conditions, including osteoporosis, cardiovascular disease, and neurodegenerative disorders.

The study also examined ovarian tissue samples from Chinese women in various age ranges. Findings showed a sharp decline in primordial follicle reserves by age 40, with reserves nearly exhausted by early 50s. But these remaining follicles could still potentially grow, supporting the idea of extending reproductive lifespan.

M-cell transplantation could be a safer and more effective approach to delay ovarian aging, as none of the treated monkeys showed signs of inflammation or other serious side effects. In comparison to untreated monkeys, the transplanted group showed improved hormone levels, follicle development, reduced fibrosis, and lower DNA damage.

The research team concluded that “M-cell transplantation is a feasible clinical strategy to alleviate physiological ovarian aging and extend fertility lifespan,” offering a new direction in fertility treatment that could improve quality of life for many women.

Source

Full Video

The post Chinese Scientists Discover Stem Cell Treatment to Combat Ovarian Aging appeared first on Journos News - Breaking News, World News, Top Stories, Todays Headlines and Flash Reports.